Enhancing the solubility and antibacterial activity of novel molecular salts of enrofloxacin drug with isomeric pyridinedicarboxylic acids
- PMID: 39592802
- PMCID: PMC11599901
- DOI: 10.1038/s41598-024-80665-y
Enhancing the solubility and antibacterial activity of novel molecular salts of enrofloxacin drug with isomeric pyridinedicarboxylic acids
Abstract
Enrofloxacin (EFX) is a third-generation synthetic fluoroquinolone with a broad spectrum of antibacterial activity but suffers from low water solubility, affecting its bioavailability. This study attempts to enhance the physicochemical and biological properties of enrofloxacin by converting it into multicomponent forms using crystal engineering concepts. Cocrystallization of enrofloxacin with isomeric pyridine-2,n-dicarboxylic acids (n = 3,4,5,6) resulted in four new crystalline salts (1:1): EFX·Py2,3DCA, EFX·Py2,4DCA, EFX·Py2,5DCA·H2O and EFX·Py2,6DCA·H2O; two of these are monohydrates. The protonation of the nitrogen atom of the piperazine moiety and the presence of crystallization water molecules were confirmed by single-crystal X-ray diffraction and Fourier transform infrared spectroscopy. Thermogravimetric analysis provided information on the thermal behaviour of multicomponent forms. The biological studies showed that the obtained salts are characterized by high antibacterial activity against Gram-positive and Gram-negative bacteria, and their haemolytic activity is low. The new salts demonstrate significantly greater solubility in water compared to the parent drug, along with enhanced antibacterial activity; hence, pyridinedicarboxylic acids appear to be efficient cocrystallizing agents for improving the efficacy of pharmaceutical ingredients.
Keywords: Antibacterial activity; Crystal engineering; Crystal structure; Enrofloxacin; Fluoroquinolones; Solubility.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures






Similar articles
-
Preparation and Physiochemical Analysis of Novel Ciprofloxacin / Dicarboxylic Acid Salts.J Pharm Sci. 2023 Jan;112(1):195-203. doi: 10.1016/j.xphs.2022.08.008. Epub 2022 Aug 8. J Pharm Sci. 2023. PMID: 35948159
-
Pharmaceutical salts/cocrystals of enoxacin with dicarboxylic acids: Enhancing in vitro antibacterial activity of enoxacin by improving the solubility and permeability.Eur J Pharm Biopharm. 2020 Sep;154:62-73. doi: 10.1016/j.ejpb.2020.06.018. Epub 2020 Jul 6. Eur J Pharm Biopharm. 2020. PMID: 32645384
-
Non-covalent binding of non-steroidal anti-inflammatory drugs to antibiotics: preparation, characterization, physicochemical properties and study of single crystals of tolfenamic acid-enrofloxacin drug-drug salt and their antibacterial and anti-inflammatory activities.Int J Pharm. 2025 Apr 30;675:125523. doi: 10.1016/j.ijpharm.2025.125523. Epub 2025 Apr 3. Int J Pharm. 2025. PMID: 40187701
-
Characterization of the solubility and solid-state properties of saccharin salts of fluoroquinolones.J Pharm Sci. 2009 Oct;98(10):3788-801. doi: 10.1002/jps.21688. J Pharm Sci. 2009. PMID: 19226631
-
Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?Int J Mol Sci. 2022 Mar 26;23(7):3648. doi: 10.3390/ijms23073648. Int J Mol Sci. 2022. PMID: 35409007 Free PMC article. Review.
References
-
- Emmerson, A. M. & Jones, A. M. The quinolones: Decades of development and use. J. Antimicrob. Chemother.51(Suppl. 1), 13–20. 10.1093/jac/dkg208 (2003). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases